Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1714-1721

  Chung, Hye Won ^a   Lim, Jong Baeck ^a   Jang, Sunphil ^a   Lee, Kyong Joo ^a   Park, Kyung Hwa ^a   Song, Si Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CHRONIC PANCREATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865773782     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02358.x     Document Type: Article

References (28)

1. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
2. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
3. Gupta MK, Arciaga R, Bocci L, Tubbs R, Bukowski R, Deodhar SD. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer 1985; 56: 277-83.
4. Akdoǧan M, Saşmaz N, Kayhan B, Biyikoǧlu I, Dişibeyaz S, Sahin B. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001; 87: 337-9.
5. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999; 10: 145-9.
6. Begent RH. The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem 1984; 21: 231-8.
7. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
8. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
9. Palumbo R, Sampaolesi M, De Marchis F et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164: 441-9.
10. Palumbo R, Galvez BG, Pusterla T et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 2007; 179: 33-40.
11. Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
12. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
13. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-40.
14. Ellerman JE, Brown CK, de Vera M et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13: 2836-48.
15. Chung HW, Lee SG, Kim H et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38-48.
16. Cheng BQ, Jia CQ, Liu CT et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40: 446-52.
17. Shang GH, Jia CQ, Tian H et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 2009; 103: 1949-53.
18. Schlueter C, Weber H, Meyer B et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005; 166: 1259-63.
19. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216: 167-75.
20. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010; 136: 677-84.
21. Huang QX, Wang GB, Sun NF, Wang CY. Inhibitory effects of high mobility group box 1 antisense nucleotide on invasion of human pancreatic cancer cell line PCNA-1. Ai Zheng 2004; 23: 1036-40.
22. Mignogna MD, Fedele S, Lo Russo L et al. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 2004; 40: 120-30.
23. Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001; 48: 1577-8.
24. Burgu B, Suer E, Aydogdu O, Soygur T. Pelvic reduction during pyeloplasty for antenatal hydronephrosis: does it affect outcome in ultrasound and nuclear scan postoperatively? Urology 2010; 76: 169-74.
25. Gall FP, Kessler H. Early cancer of the exocrine pancreas: diagnosis and prognosis. Chirurg 1987; 58: 78-83.
26. Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003; 49: 1-6.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-72.
28. Dong XE, Ito N, Lotze MT et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007; 30: 596-606.